A phase I dose escalation of combination chemotherapy with granulocyte- macrophage-colony stimulating factor in patients with neuroblastoma

Cancer

Volumn 88, Issue 12, 2000, Pages 2838-2844

  Fernandez, M Carmen ^a   Krailo, Mark D ^b   Gerbing, Robert R ^b   Matthay, Katherine K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Chemotherapy; Combination chemotherapy; Cytokines; Pediatric solid tumors; Recurrent neuroblastoma

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFANT; LUNG TOXICITY; MALE; MAXIMUM PERMISSIBLE DOSE; NEPHROTOXICITY; NEUROBLASTOMA; NEUROEPITHELIOMA; NEUTROPENIA; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; NEUTROPENIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034660123     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12<2838::AID-CNCR25>3.0.CO;2-9     Document Type: Article

References (27)

1. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998;16(3):953-65.
2. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies [see comments]. J Clin Oncol 1996;14(9):2417-26.
3. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma [see comments]. J Clin Oncol 1991;9(6):1050-8.
4. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 anti-body on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991;51(1):144-9.
5. Herrmann F, Schulz G, Wieser M, Kolbe K, Nicolay U, Noack M, et al. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am J Med 1990;88(6):619-24.
6. Campbell LA, Seeger RC, Harris RE, Villablanca JG, Matthay KK. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 1993;11(4):623-9.
7. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993;11(8):1466-77.
8. Turnbull BW. The empirical function from arbitrarily grouped, censored and truncated data. J R Stat Soc B 1976; (38):290-5.
9. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78(11):2791-808.
10. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991;77(6):1131-45.
11. Carpenter PA, White L, McCowage GB, Nayanar V, Toogood I, Shaw PJ, et al. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group. Cancer 1997;80(3):489-96.
12. Alvarado CS, Kretschmar C, Joshi VV, Toledano S, Cantor A, Strother D, et al. Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study. J Pediatr Hematol Oncol 1997;19(1):62-7.
13. Kreissman SG, Rackoff W, Lee M, Breitfeld PP. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol Oncol 1997;19(4):309-12.
14. Saylors RI, III, Stewart CF, Zamboni WC, Wall DA, Bell B, Stine KC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 1998;16(3):945-52.
15. Kung FH, Desai SJ, Dickerman JD, Goorin AM, Harris MB, Inoue S, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 1995;17(3):265-9.
16. Marina NM, Rodman J, Shema SJ, Bowman LC, Douglass E, Furman W, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol 1993;11(3): 554-60.
17. McCowage GB, White L, Carpenter P, Lockwood L, Toogood I, Tiedemann K, et al. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group. Med Pediatr Oncol 1997;29(2):108-14.
18. Weiss RB. Ifosfamide vs cyclophosphamide in cancer therapy. Oncology 1991;5(5):67-76; discussion -82, 4-6.
19. Ozols RF, Behrens BC, Ostchega Y, Young RC. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 1985;12(Suppl A):59-65.
20. Lowis SP, Pearson ADJ, Reid MM, Craft AW. Prohibitive toxicity of a dose-intense regimen for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. Cancer Chemother Pharmacol 1993;31(5):415-8.
21. Di Caro A, Bostrom B, Moss TJ, Neglia J, Ramsay NK, Smith J, et al. Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma. Am J Pediatr Hematol Oncol 1994;16(3):200-6.
22. Stern J, Mogul M, Adams R, Grier H, Gorlin K, Marcus K, et al. Tandem high dose therapy for children with high-risk neuroblastoma and metastatic sarcomas [abstract 504]. Presented at: Proceedings of the American Society of Pediatric Hematology/Oncology Annual Meeting, 1998.
23. Alexander WS. Cytokines in hematopoiesis. Int Rev Immunol 1998;16(5-6):651-82.
24. Cairo MS, Krailo MD, Weinthal JA, Secola R, Bergeron S, van de Ven C, et al. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tu-mors: a report of the Children's Cancer Group. Cancer 1998; 83(7):1449-60.
25. Philip T, Ghalie R, Pinkerton R, Zucker JM, Bernard JL, Leverger G, et al. A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1987;5(6):941-50.
26. Michon JM, Hartmann O, Bouffet E, Meresse V, Coze C, Rubie H, et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer 1998;34(7):1063-9.
27. Keshelava N, Seeger RC, Reynolds CP. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. Eur J Cancer 1997;33(12):2002-6.